2 recruiting, 1 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Spinal Dysraphism: new trials by email Literature Review of Spinal Dysraphism trials Research Report on Spinal Dysraphism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction Oxybutynin Hydrochloride, Placebo - Spina Bifida | Phase 3 | Recruiting | Central Hospital, Nancy, France | 60 | 2026-01-15 | 2026-04-14 |
| Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC Vibegron - Neurogenic Detrusor Overactivity | Phase 2 / Phase 3 | Recruiting | Urovant Sciences GmbH | 71 | 2022-10-12 | 2026-06-15 |
| A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives Norgestimate-ethinyl estradiol, with or without folic acid - Neural Tube Defects, Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Phase 3 | Withdrawn | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2016-09-20 |
Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Meningocele (1) · Meningomyelocele (1) · Myelitis, Transverse (1) · Nervous System Diseases (1) · Nervous System Malformations (1) · Neural Tube Defects (1) · Spinal Cord Injuries (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neural Tube Defects (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Hernia (1) · Immune System Diseases (1) · Infections (1) · Myelitis (1)
Administration, Intravesical (1) · Moxifloxacin (1) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (1) · oxybutynin (1)
Central Hospital, Nancy, France (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Urovant Sciences GmbH (1)
Belgium (1) · Canada (1) · Croatia (1) · Denmark (1) · France (1) · Georgia (1) · Jordan (1) · Latvia (1) · Lithuania (1) · Malaysia (1) · Philippines (1) · Poland (1) · Romania (1) · Serbia (1) · Slovakia (1)